|Bid||8.00 x N/A|
|Ask||9.25 x N/A|
|Day's Range||8.72 - 8.72|
|52 Week Range||1.90 - 9.94|
|Beta (5Y Monthly)||1.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER, BC, July 28, 2020 /CNW/ - The following issues have been halted by IIROC: Company: ESSA Pharma Inc.TSX-Venture Symbol: EPIAll Issues: YesReason: At the Request of the Company Pending NewsHalt Time (ET): 3:53 PMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.
HOUSTON and VANCOUVER, BC , July 15, 2020 /CNW/ - ESSA Pharma Inc. (EPIX) (EPI.V), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in a Phase 1 clinical trial designed to demonstrate the safety and tolerability of EPI-7386 in metastatic castration-resistant prostate cancer ("mCRPC") patients who failed standard of care treatments, including second generation anti-androgens. EPI-7386 is a small molecule inhibitor of the N-terminal domain of the androgen receptor (AR) which has shown preclinical activity in both anti-androgen sensitive and anti-androgen resistant prostate cancer models.
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II